The Impact of Lactotripeptides on Blood Pressure Response in Stage 1 and Stage 2 Hypertensives
Article first published online: 19 JAN 2010
© 2010 Wiley Periodicals, Inc.
The Journal of Clinical Hypertension
Volume 12, Issue 3, pages 153–159, March 2010
How to Cite
Germino, F. W., Neutel, J., Nonaka, M. and Hendler, S. S. (2010), The Impact of Lactotripeptides on Blood Pressure Response in Stage 1 and Stage 2 Hypertensives. The Journal of Clinical Hypertension, 12: 153–159. doi: 10.1111/j.1751-7176.2009.00250.x
- Issue published online: 19 FEB 2010
- Article first published online: 19 JAN 2010
- Manuscript received April 25, 2009; revised August 17, 2009; accepted October 31, 2009
J Clin Hypertens (Greenwich). 2010;12:153–159. ©2010 Wiley Periodicals, Inc.
Nearly 70 million Americans have hypertension, and approximately an equal number have prehypertension. The prevalence of both disorders increases with advancing age and obesity. Many at-risk individuals do not have controlled blood pressure (BP). Lifestyle modification for most persons is the first step in a plan to control these conditions. Non–drug treatments offer an appeal to many patients with modest BP elevation. The authors recently evaluated BP response using 24-hour ambulatory BP monitoring and office BP monitoring of lactotripeptides dosed twice daily in 91 previously treated and treatment-naive patients with stage 1 and stage 2 hypertension. In this population, daytime systolic BP, the primary efficacy end point, significantly decreased (−3.6 mm Hg; P=.013), while placebo did not affect systolic BP (0 mm Hg; P=not significant). Treatment-naive patients exhibited a more robust drop in their daytime systolic BP (−7.6 mm Hg; P=.005) compared with placebo (−3.6 mm Hg; P=not significant). Lactotripeptides may be an effective agent in the management of low-risk and low-grade hypertension and prehypertension.